Previous 10 | Next 10 |
Oncorus shares have been in steady decline since nearly doubling in value less than six months after the company's October 2020 IPO. Current trading price of $13 is slightly under the $15 IPO price, but the biotech has just entered the clinic with its first viral oncolytic therapy, ON...
-- Renowned academic and industry leader brings deep expertise in oncology translational research and drug development, including pioneering work at Merck on KEYTRUDA® (pembrolizumab) -- CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clini...
Virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ET Oncorus’ novel approach leverages selectively self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid nanoparticles (LNPs) Oncorus’ leadership will discuss its Synthe...
Pioneering Synthetic vRNA immunotherapies that are composed of self-amplifying vRNA encoding for oncolytic viruses encapsulated within lipid nanoparticles (LNPs) Novel approach engineered to produce a living immunostimulatory drug in the form of infectious virions in the tumor to dest...
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will...
Oncorus (ONCR): Q1 GAAP EPS of -$0.53 beats by $0.01.Cash and cash equivalents of $172.6M.Press Release For further details see: Oncorus EPS beats by $0.01
-- Enrollment continues in Phase 1 clinical trial of lead oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy candidate ONCR-177; initial interim data expected in 2H’21 -- -- Company plans to nominate first two intravenously (IV) administered synthetic viral RNA...
The Wall Street analysts have reviewed their coverage on TG Therapeutics and Oncorus after recent developments while initiating buy-equivalent ratings on Olink, Outset Medical, and Lava Therapeutics.Jefferies sees a compelling risk-reward profile in BiogenNoting that the Street is estimating ...
The following slide deck was published by Oncorus, Inc. in conjunction with this event. For further details see: Oncorus (ONCR) Investor Presentation - Slideshow
Oncorus (ONCR): Q4 GAAP EPS of -$0.56 misses by $0.08.Cash and cash equivalents of $130.3MPress Release For further details see: Oncorus EPS misses by $0.08
News, Short Squeeze, Breakout and More Instantly...
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...